Dr.

<p>Figure S1. Schematic experimental design. (A) Experiment 1 was performed to evaluate the protective effects of different concentrations of ART on functional behavioral test after MCAO. (B) Experiment 2 was carried out to examine the efficacy of ART, and to identify the underlying mechanisms of its neuroprotective effects on experimental MCAO model. MRI, magnetic resonance imaging; DTI, diffusion tensor imaging; TTC, 2, 3, 5-triphenyltetrazolium hydrochloride staining; TEM, transmission electron microscopy; IF, immunofluorescence; WB, western blotting; ART: artesunate; FOXO3a^OE: overexpression of FOXO3a in nucleus through mutant type Ad-(triple mutant)-FOXO3a recombinant adenovirus vectors.</p> <p>&nbsp;</p> <p>Figure S2. Administration of ART or/and overexpression of FOXO3a exhibited no effects on mice survival rate and body weight. (A and B) Survival rate and body weight changes measured at 0, 1, 3, 7 and 14 days post-MCAO. Data are presented as the Mean&plusmn;SEM (n&ge;6 in each group). ART: artesunate; FOXO3aOE: overexpression of FOXO3a in nucleus through mutant type Ad-(triple mutant)-FOXO3a recombinant adenovirus vectors; NS: no significance.</p> <p>&nbsp;</p> <p>Figure S3. Transfection efficiency of overexpressed FOXO3a was analyzed by Western blot 24h after MCAO (72h after virus injection). (A) Representative western blotting for FOXO3a; (B) Quantification of western blots for FOXO3a.</p> <p>&nbsp;</p> <p><strong>Figure S4.</strong> FOXO3a is involved in ART-modulated neurogenesis in SVZ after MCAO. (A) Representative immunostaining of Brdu+ in SVZ 3 days after MCAO (Scale bar=100 &mu;m). (B) Quantitative analyses of the fluorescence intensity of Brdu+.</p> <p>Figure S1. Schematic experimental design. (A) Experiment 1 was performed to evaluate the protective effects of different concentrations of ART on functional behavioral test after MCAO. (B) Experiment 2 was carried out to examine the efficacy of ART, and to identify the underlying mechanisms of its neuroprotective effects on experimental MCAO model. MRI, magnetic resonance imaging; DTI, diffusion tensor imaging; TTC, 2, 3, 5-triphenyltetrazolium hydrochloride staining; TEM, transmission electron microscopy; IF, immunofluorescence; WB, western blotting; ART: artesunate; FOXO3a^OE: overexpression of FOXO3a in nucleus through mutant type Ad-(triple mutant)-FOXO3a recombinant adenovirus vectors.</p> <p>&nbsp;</p> <p>Figure S2. Administration of ART or/and overexpression of FOXO3a exhibited no effects on mice survival rate and body weight. (A and B) Survival rate and body weight changes measured at 0, 1, 3, 7 and 14 days post-MCAO. Data are presented as the Mean&plusmn;SEM (n&ge;6 in each group). ART: artesunate; FOXO3aOE: overexpression of FOXO3a in nucleus through mutant type Ad-(triple mutant)-FOXO3a recombinant adenovirus vectors; NS: no significance.</p> <p>&nbsp;</p> <p>Figure S3. Transfection efficiency of overexpressed FOXO3a was analyzed by Western blot 24h after MCAO (72h after virus injection). (A) Representative western blotting for FOXO3a; (B) Quantification of western blots for FOXO3a.</p> <p>&nbsp;</p> <p><strong>Figure S4.</strong> FOXO3a is involved in ART-modulated neurogenesis in SVZ after MCAO. (A) Representative immunostaining of Brdu+ in SVZ 3 days after MCAO (Scale bar=100 &mu;m). (B) Quantitative analyses of the fluorescence intensity of Brdu+.</p>